Zai Lab Rises Nearly 5% in Morning Session Following Global Clinical Research Collaboration with Amgen

Deep News04-02

Zai Lab (09688) saw an increase of over 4% in morning trading. At the time of writing, the stock was up 4.82%, trading at HK$15.88 with a turnover of HK$288 million.

On April 1, Zai Lab announced a global clinical research collaboration with Amgen. The partnership aims to evaluate Zai Lab's clinical-stage antibody-drug conjugate (ADC) zocilurtatug pelitecan (zoci, formerly known as ZL-1310), which targets delta-like ligand 3 (DLL3), in combination with Amgen's IMDELLTRA® (tarlatamab), a bispecific T-cell engager (BiTE®) therapy targeting DLL3, for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

As part of the agreement, Amgen will sponsor a global Phase 1b study to assess the safety and efficacy of zoci in combination with IMDELLTRA® in ES-SCLC patients. Zai Lab will retain full ownership of zoci and will supply the investigational drug for the clinical study.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment